Publications by authors named "Gabor Tatai"
Allogeneic hematopoietic stem cell transplantation (HSCT) and coronavirus disease 2019 (COVID-19) infection can both lead to severe cytokine release syndrome (sCRS) resulting in critical illness and death. In this single institution, preliminary comparative case-series study we compared clinical and laboratory co-variates as well as response to tocilizumab (TCZ)-based therapy of 15 allogeneic-HSCT- and 17 COVID-19-associated sCRS patients. Reaction to a TCZ plus posttransplant cyclophosphamide (PTCY) consolidation therapy in the allogeneic-HSCT-associated sCRS group yielded significantly inferior long-term outcome as compared to TCZ-based therapy in the COVID-19-associated group (P = 0.
View Article and Find Full Text PDFArticle Synopsis
- Autologous hemopoietic stem cell transplantation is a treatment option for both malignant and non-malignant conditions, but it comes with a heightened risk of infections early and late after the procedure.
- A study analyzing 699 patients found that 69.8% experienced neutropenic fever, with most infections being bacteremia, particularly prevalent in lymphoma patients compared to those with plasma cell disorders.
- Early infections, especially bacteremia, were linked to increased mortality risk, emphasizing the need for effective preventative measures and treatments in patients undergoing this type of transplantation.*